Stay updated on PATHWay Study: Adjuvant Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now displays a new revision label 'Revision: v3.4.2', and the prior general funding/operating status notice was removed. These are administrative changes that do not affect the study content, eligibility criteria, or outcomes.
    Difference
    0.5%
    Check dated 2026-02-11T01:20:58.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and the NIH Clinical Center's status, with guidance to visit cc.nih.gov and opm.gov; updated the revision tag to v3.4.1 (replacing v3.4.0).
    Difference
    0.5%
    Check dated 2026-02-03T22:10:21.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now displays new metadata fields: 'Last Update Submitted that Met QC Criteria' and 'Last Update Posted', and shows 'No FEAR Act Data' along with Revision: v3.4.0. The previous fields were 'Last Update Submitted that met QC Criteria', 'Last Update Posted (Estimated)', 'No FEAR Act data', and Revision: v3.3.4, which have been removed.
    Difference
    0.3%
    Check dated 2026-01-27T16:44:23.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Page revision updated to v3.3.4 from v3.3.3; this appears to be a metadata/version update with no visible changes to the study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-20T14:38:17.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Locations section now consolidates the study sites under Georgia, Illinois, and Pennsylvania, replacing separate location pages. The HHS Vulnerability Disclosure link has been removed.
    Difference
    0.5%
    Check dated 2025-12-22T22:26:02.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.2 replacing v3.3.1, and the study details appear unchanged aside from the revision label. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T11:51:45.000Z thumbnail image

Stay in the know with updates to PATHWay Study: Adjuvant Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.